Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
FLFulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT)

NASDAQ Global Market · Currency in USD
$20.10 ▲ +0.11 (+0.55%)
At close: Oct 23, 4:00 PM ET. Market closed.
$20.10 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$19.99
Open
$19.85
Day's Range
$19.69 – $20.28
52 Week Range
$13.46 – $31.04
Volume
240,056
Avg. Volume
295,175
Market Cap
$553.06M
Beta (5Y Monthly)
0.93
PE Ratio (TTM)
--
EPS (TTM)
-$3.01
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$19.00

Profile: Fulgent Genetics, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
1,315
CEO
Ming Hsieh

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.65 · Revenue est. $86.30M
DateEst.Actual
Jul 30, 2026-$0.46-$0.58Miss
May 1, 2026-$0.35-$0.36Miss
Feb 27, 2026$0.03$0.16Beat
Nov 7, 2025-$0.24$0.14Beat
Aug 1, 2025-$0.23$0.07Beat
May 2, 2025-$0.19$0.04Beat

Analyst view

Consensus price target
$19.00 ▼ -5.5%
Range $19.00 – $19.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on FLGT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.